Rivaroxaban is an oral anti-clotting substance (anticoagulant drug) which is used in the following instances: to prevent venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients undergoing hip or knee replacement surgery; to prevent stroke and systemic embolism (in patients with atrial fibrillation); to treat DVT and PE and to reduce the risk of recurrent DVT and PE.
Rivaroxaban is also approved in the EU for use in patients with acute coronary syndromes to reduce the risk of cardiovascular events.
An oral suspension of rivaroxaban for pediatric use is in clinical development.
As of May 2014, Rivaroxaban is approved in over 100 countries worldwide for different indications.
Rivaroxaban was approved under the trade name Xarelto in Canada and the EU in 2008, and in the US in 2012.